<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: Re: Performance enhancement with selegiline</title>
<meta name="Author" content="Rafal Smigrodzki (rafal@smigrodzki.org)">
<meta name="Subject" content="Re: Performance enhancement with selegiline">
<meta name="Date" content="2003-02-15">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>Re: Performance enhancement with selegiline</h1>
<!-- received="Sat Feb 15 22:13:23 2003" -->
<!-- isoreceived="20030216051323" -->
<!-- sent="Sun, 16 Feb 2003 00:13:19 -0500" -->
<!-- isosent="20030216051319" -->
<!-- name="Rafal Smigrodzki" -->
<!-- email="rafal@smigrodzki.org" -->
<!-- subject="Re: Performance enhancement with selegiline" -->
<!-- id="002d01c2d57a$1fd25680$6401a8c0@dimension" -->
<!-- charset="iso-8859-1" -->
<!-- inreplyto="01b801c2d52e$3638cfe0$c05e87d8@pavilion" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> Rafal Smigrodzki (<a href="mailto:rafal@smigrodzki.org?Subject=Re:%20Performance%20enhancement%20with%20selegiline"><em>rafal@smigrodzki.org</em></a>)<br>
<strong>Date:</strong> Sat Feb 15 2003 - 22:13:19 MST
</p>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2783.html">Rafal Smigrodzki: "Re: Performance enhancement with selegiline"</a>
<ul>
<li><strong>Previous message:</strong> <a href="2781.html">Rafal Smigrodzki: "Re: Images in the brain of the dead was RE: Where the I is"</a>
<li><strong>In reply to:</strong> <a href="2760.html">gts: "Re: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2310.html">Alex Ramonsky: "Re: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2782">[ date ]</a>
<a href="index.html#2782">[ thread ]</a>
<a href="subject.html#2782">[ subject ]</a>
<a href="author.html#2782">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
----- Original Message -----
<br>
From: &quot;gts&quot; &lt;<a href="mailto:gts_2000@yahoo.com?Subject=Re:%20Performance%20enhancement%20with%20selegiline">gts_2000@yahoo.com</a>&gt;
<br>
To: &lt;<a href="mailto:extropians@extropy.org?Subject=Re:%20Performance%20enhancement%20with%20selegiline">extropians@extropy.org</a>&gt;
<br>
Sent: Saturday, February 15, 2003 3:09 PM
<br>
Subject: Re: Performance enhancement with selegiline
<br>
<p><p><em>&gt; For those of you with open minds and optimistic attitudes, here is yet
</em><br>
<em>&gt; *another* research abstract about the benefits of selegiline. (I think
</em><br>
I've
<br>
<em>&gt; posted at least a dozen such abstracts now!)
</em><br>
<p>### Another meaningless dog study.
<br>
<p>-----------------------
<br>
<p><em>&gt;
</em><br>
<em>&gt; Rafal, as far as I can tell you are not interested in fairly evaluating
</em><br>
<em>&gt; selegiline (deprenyl). You seem entrenched in your close-minded role as
</em><br>
<em>&gt; nay-sayer. I'm quite sure there is nothing I could post here short of
</em><br>
<em>&gt; absolute proof positive that would persuade you of the immense promise of
</em><br>
<em>&gt; this drug for life-extension and cognitive enhancement purposes. Oh well!
</em><br>
<em>&gt; I'm not posting these messages here only for your benefit.
</em><br>
<p>### Find a placebo-controlled, preferably multicenter, definitely
<br>
double-blind trial with positive results and I'll join your camp. All else
<br>
is a waste of time.
<br>
<p>Until then, whoever wants to spend his cash on this drug will do it without
<br>
my blessing.
<br>
<p>----------------------
<br>
<p><em>&gt;
</em><br>
<em>&gt; Your attitude by the way also argues against the practice of calorie
</em><br>
<em>&gt; restriction in humans, despite its numerous successes in prolonging life
</em><br>
in
<br>
<em>&gt; lab animals.
</em><br>
<p>### Well, there is evidence that caloric restriction reduces blood pressure,
<br>
insulin resistance, lipid peroxidation, and some other markers of aging in
<br>
humans. This is not proof of CR efficacy but strong-willed adventurers might
<br>
find these data compelling enough. On the other hand we have to remember the
<br>
lesson of the reduction of PVC's - there were drugs widely prescribed
<br>
against cardiac arrhythmias, because the effectively prevented PVC's, which
<br>
were considered markers of a tendency to have arrhythmias. Unfortunately,
<br>
later on it turned out that these drugs were also causing the patients to
<br>
die. Or, the same story with HRT - prescribed on the basis of markers, and
<br>
symptomatic relief, but now proven to actually kill patients.
<br>
<p>Buyer beware.
<br>
<p>Rafal
<br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2783.html">Rafal Smigrodzki: "Re: Performance enhancement with selegiline"</a>
<li><strong>Previous message:</strong> <a href="2781.html">Rafal Smigrodzki: "Re: Images in the brain of the dead was RE: Where the I is"</a>
<li><strong>In reply to:</strong> <a href="2760.html">gts: "Re: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2310.html">Alex Ramonsky: "Re: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2782">[ date ]</a>
<a href="index.html#2782">[ thread ]</a>
<a href="subject.html#2782">[ subject ]</a>
<a href="author.html#2782">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Sat Feb 15 2003 - 22:15:46 MST
</em></small></p>
</body>
</html>
